Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL246840 | 0.85 | ACHE (0.42) | ACHECES2CES1MAOBPTPN1 | |
| SCHEMBL2953875 | 0.85 | PTPN1 (0.57) | CES2CES1KIF11MAOBPTPN1 | |
| SCHEMBL12430465 | 0.84 | ACHE (0.44) | ACHECES2CES1PTPN1MAPT | |
| SCHEMBL1349781 | 0.83 | MAPT (0.54) | MAPTRAB9ANPC1ALDH1A1HPGD | |
| SCHEMBL2686773 | 0.83 | GSK3B (0.47) | CES2CES1KIF11MAOBPTPN1 | |
| SCHEMBL671907 | 0.82 | CES2 (0.61) | ACHECES2CES1MAOBMAPT | |
| SCHEMBL22097341 | 0.80 | KMT2A (0.49) | MAPTRAB9ANPC1ALDH1A1HPGD | |
| SCHEMBL6313789 | 0.80 | MAPT (0.56) | MAPTRAB9ANPC1ALDH1A1HPGD | |
| SCHEMBL23617623 | 0.79 | KIF11 (0.42) | CES2CES1KIF11MAOBPTPN1 | |
| SCHEMBL16563526 | 0.79 | SLC6A4 (0.44) | MAPTRAB9AHDAC1HDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456156-B2 | Aryl boronic acids for treating obesity | GENZYME CORPORATION (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1404685-B1 | ARYL BORONIC ACIDS FOR TREATING OBESITY | GENZYME CORP (US) | 2006-09-13 | — | — | EP | disclosed |
| US-20060128663-A1 | Aryl boronate functionalized polymers for treating obesity | GENZYME CORPORATION (US) | 2006-06-15 | — | — | US | disclosed |
| US-20060128664-A1 | Aryl boronic acids for treating obesity | GENZYME CORPORATION (US) | 2006-06-15 | — | — | US | disclosed |
| US-7049304-B2 | Aryl boronic acids for treating obesity | GENZYME CORPORATION (US) | 2006-05-23 | — | — | US | disclosed |
| US-7041280-B2 | Aryl boronate functionalized polymers for treating obesity | GENZYME CORPORATION (US) | 2006-05-09 | — | — | US | disclosed |
| US-20050107336-A1 | Aryl boronic acids for treating obesity | HOLMES-FARLEY STEPHEN R (US) | 2005-05-19 | — | — | US | disclosed |
| US-6858592-B2 | Aryl boronic acids for treating obesity | GENZYME CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1404686-A1 | ARYL BORONATE FUNCTIONALIZED POLYMERS FOR TREATING OBESITY | Geltex Pharmaceuticals, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-1404685-A1 | ARYL BORONIC ACIDS FOR TREATING OBESITY | Geltex Pharmaceuticals, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030064963-A1 | Aryl boronic acids for treating obesity | GELTEX PHARMACEUTICALS, INC. | 2003-04-03 | — | — | US | disclosed |
| US-20030059399-A1 | Aryl boronate functionalized polymers for treating obesity | GELTEX PHARMACEUTICALS, INC. | 2003-03-27 | — | — | US | disclosed |
| WO-2003002570-A1 | ARYL BORONIC ACIDS FOR TREATING OBESITY | GENZYME CORPORATION (US) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003002571-A1 | ARYL BORONATE FUNCTIONALIZED POLYMERS FOR TREATING OBESITY | GENZYME CORPORATION (US) | 2003-01-09 | — | — | WO | disclosed |
| US-5786350-A | CONDENSATION; HYDROLYSIS; DEPROTECTING | GRUPPO LEPETIT S.P.A. (IT) | 1998-07-28 | — | — | US | disclosed |
| US-5169853-A | Antibacterial agents; administering to mammals for infection | STERLING DRUG INC. (US) | 1992-12-08 | — | — | US | disclosed |
| US-5075319-A | Bactericides | STERLING DRUG INC. (US) | 1991-12-24 | — | — | US | disclosed |
| EP-0417669-A2 | Pyridinyl-quinolone compounds, their preparation and use | STERLING WINTHROP INC. (US) | 1991-03-20 | — | — | EP | disclosed |
| EP-0309789-A1 | 4-Oxo-3-quinolinecarboxylic acids useful as antibacterial agents and preparation thereof | STERLING WINTHROP INC. (US) | 1989-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128664-A1 | Aryl boronic acids for treating obesity | FFAR3, NR1H4, NR1H3 | ACHE 4325/4885CES2 461/4885CES1 162/4885 |
| US-20030059399-A1 | Aryl boronate functionalized polymers for treating obesity | CEL, AHR, LIPE | ACHE 3976/4885CES2 47/4885CES1 82/4885 |
| US-20050107336-A1 | Aryl boronic acids for treating obesity | FFAR3, NR1H3, NR1H4 | ACHE 4338/4885CES2 457/4885CES1 162/4885 |
| US-20030064963-A1 | Aryl boronic acids for treating obesity | FFAR3, FFAR1, NR1H3 | ACHE 4562/4885CES2 413/4885CES1 89/4885 |
| US-20060128663-A1 | Aryl boronate functionalized polymers for treating obesity | CEL, AHR, LIPE | ACHE 4190/4885CES2 51/4885CES1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.